Introduction
Hepatitis C virus (HCV) is a virus that is a common cause of viral hepatitis. Untreated HCV can lead to chronic liver disease, including cirrhosis, organ failure and liver cancer. An estimated 150-170 million people worldwide are chronically infected with HCV and have an increased risk of developing liver cirrhosis or liver cancer (Lavanchy, 2011; Mohd Hanafiah et al., 2013) .
Genotype 1 is the most prevalent genotype in the United States, Europe, and Japan, and globally accounts for approximately 60% of HCV infections (Zein, 2000) .
HCV is an enveloped positive-strand RNA virus that replicates primarily in the cytoplasm of hepatocytes. Viral NS3-4A serine protease is a non-covalent heterodimer consisting of a catalytic subunit (the N-terminal one-third of NS3 protein) and an activating cofactor (NS4A protein), which is responsible for cleavage of the HCV polyprotein at four sites. HCV NS3-4A protease is essential for the viral replication process (Lin, 2006; Moradpour et al., 2007) and is a validated drug target (McHutchison et al., 2009; Poordad et al., 2011) . Paritaprevir (ABT-450) is a potent macrocyclic noncovalent peptidomimetic inhibitor (identified by AbbVie and Enanta ) of HCV NS3/4A protease, with 50% effective concentration values of 1.0, 0.21, 5.3, 19, 0 .09, and 0.69 nM against stable HCV replicons with NS3 protease from genotypes 1a, 1b, 2a, 3a, 4a, and 6a, respectively (Pilot-Matias et al., 2015) . Paritaprevir with ritonavir demonstrated robust D M D # 0 6 7 4 8 8 5 Kowdley et al., 2014; Zeuzem et al., 2014) . Treatment with paritaprevir/r-ombitasvir and dasabuvir with ribavirin showed higher rates of sustained virologic response among patients with genotype 1a infection compared to that in the ribavirin-free group (Ferenci et al., 2014) .
Paritaprevir is metabolized primarily by cytochrome P450 CYP3A4 (Bernstein et al., 2009 ). To mitigate the high first-pass and hepatic elimination, paritaprevir is co-administered with a low dose of ritonavir, a potent CYP and efflux transport inhibitor, as a boosting agent to improve systemic exposure. Clinical results confirmed that co-administration of ritonavir increases paritaprevir plasma levels and half-life, permitting once-daily dosing (Menon et al., 2009) . A 100-mg ritonavir dose was found to be optimal for increasing paritaprevir exposure without negatively impacting the safety profile (Menon et al., 2015) . The pharmacokinetics of paritaprevir increased in a greater than dose-proportional fashion and showed a 2-3 fold accumulation following multiple dosing (Bernstein et al., 2009) . Paritaprevir was shown to be safe, well tolerated with minimal side effects in genotype 1 HCV-infected treatment-naïve subjects (Lawitz et al., 2010) . This report describes the metabolism and disposition of a single
200-mg oral dose of [
Paritaprevir ((2R,6S,12Z,13aS,14aR,16aS )-N-(cyclopropylsulfonyl)-6-{[(5-methylpyrazin-2-yl)carbonyl]amino}-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2, 3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e] Radiochemical purity was >99% after HPLC purification. 5-Methylpyrazine 2-carboxylic acid (M13) was obtained from Sigma-Aldrich. All these reference standards were used as HPLC and mass spectrometric standards for structure confirmation.
Clinical Study
The clinical study was conducted at Covance Laboratories Inc., in conjunction with the Covance Clinical Research Unit (Madison, WI) . In this open-label study, a total of four adult male subjects (N = 4) in general good health were selected to participate in the study according to the selection criteria. On the morning of Study Day 1, subjects received a single oral dose of Blood samples were collected by venipuncture into potassium EDTA vacutainer collection tubes at the following times: 0 hour (predose), 1, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post dose. Plasma was separated via centrifugation and stored at -70°C. 
Total Radioactivity Measurement by Liquid Scintillation Counting
All sample combustions were conducted using a Model 307 Sample Oxidizer (Packard Instrument Company) and the resulting 14 CO 2 was trapped in a mixture of Perma Fluor and Carbo Sorb. The oxidation efficiency was evaluated daily of sample combustion by analyzing a commercial radiolabeled standard both directly in scintillation cocktail and by oxidation.
Acceptance criteria were defined as combustion recoveries of 95 to 105%. Ultima Gold XR scintillation cocktail was used for samples analyzed directly. All samples were analyzed for radioactivity in Model 2900TR liquid scintillation counters (Packard Instrument Company) for at least 5 minutes or 100,000 counts. Each sample was homogenized or mixed with scintillation cocktail before radioanalysis. All samples were analyzed in duplicate if sample size allowed. If results from sample replicates (calculated as 14 C dpm/g sample) differed by more than 10% from the mean value and sample aliquots had radioactivity greater than 200 dpm, the sample was rehomogenized and reanalyzed. 
Sample Preparation for Metabolite Profiling
Plasma samples were thawed at the room temperature and pooled across subjects at selected time points or using the Hamilton method (also known as time-point weighted AUC pool) (Hamilton et al., 1981) for each subject. Plasma samples were processed using a two-step extraction method. In brief, pooled plasma was extracted with a two-fold volume of acetonitrile dissolved in 5 mL ACN:methanol (3:1, v/v) for solid phase extraction (SPE) using the Varian MEGA BE-C8 Bond Elut (Part# 12256002). The cartridge was conditioned using 2 x 5 mL ACN:methanol (3:1, v/v) and 2 x 5 mL 0.1% formic acid in water. The cartridge was pre-filled with 4.5 mL of deionized water with the stopcock closed and 0.5 mL of the extracted sample was loaded, mixing well before opening the stopcock to initiate the flow through the cartridge. Once the sample was loaded, the process was repeated until all the extracted sample was loaded to the column. The cartridge was washed with 5 mL deionized water and the sample was eluted with 3 x 5 mL ACN:methanol (3:1, v/v). The eluent was evaporated to dryness under a nitrogen stream at room temperature, and residue was reconstituted in 75 µL ACN:methanol (3:1, v/v), diluted with 150 µL of water before HPLC-MS-radiochemical detection analysis. An aliquot of the reconstituted sample was subjected to LSC counting to determine the total radioactivity recovery. The mean radioactivity recovery in the processed plasma samples was about 83%.
Pooled urine was extracted using SPE. In brief, SPE cartridge (Phenomenex Strata X-AW 33 µ Polymeric Weak Anion, 1 g/12 mL, Part# 8B-S038-HDG) was conditioned with 15 mL methanol and 15 mL deionized water. Aliquots of pooled urine were loaded to the pre- recovered or until less than 2% of the radioactivity was extracted. Aliquots of extracted samples were subjected to LSC counting for total radioactivity. The extract was dried down under the nitrogen stream at room temperature, and the final residues were reconstituted in initial mobile phase for LC-MS-radiodetection analysis. An aliquot of the reconstituted solution was subject to LSC radiocounting for extraction recovery calculation. The overall extraction recovery for fecal sample was about 92%.
Method for Metabolite Profiles and Identification
HPLC separation of paritaprevir and metabolites was conducted using a Thermo Accela UHPLC Radioactivity counting was conducted using Perkin-Elmer TopCount NXT system..
Quantitation of Metabolite M2 in Human Plasma
A Following a brief mixing, 850 µL of ethyl acetate and hexane (9:1, by volume) was added to the sample. After mixing and centrifugation, 500 µL of the organic extract was transferred to a clean 96-well plate and evaporated to dryness under a stream of dry nitrogen at room temperature. The samples were reconstituted with 300 µL mobile phase for LC-MS analysis.
M2 and IS were separated on a 50 x 3 mm 2.7 µm Ascentis Express C18 (Supelco) column with an acetonitrile: 0.1% aqueous formic acid mobile phase containing 0.025% trifluoroacetic acid for IS. M2 and IS peak areas were determined using Sciex TurboQuan software. The plasma drug concentration of each sample was calculated by least squares linear regression analysis of the peak area ratio (parent / IS) of the spiked plasma standards versus concentration.
Pharmacokinetic Calculations
Plasma concentration-time radioactivity data were analyzed with SAS software (version 9.2; SAS Institute Inc., Cary, NC). Maximum plasma concentration (C max ), time at which C max was achieved (T max ), area under the concentration time curve from time zero to last measurable time point (AUC 0-t ) for total radioactivity, [ 14 C]paritaprevir , ritonavir and its metabolites in plasma were estimated. Area under the concentration time curve from time zero to infinity (AUC 0-∞ ) and half-life (t 1/2 ) for total radioactivity, [ 14 C]paritaprevir in plasma were also calculated.
In Vitro Studies
Human Fecal Incubations. Fresh fecal samples were collected from two healthy male subjects.
Aliquots of specimen (approx. 1 gram) were placed into pre-weighted 15 mL centrifuge tubes with screw caps. The sample tubes were kept in an AnaeroPouch (Mitsubishi Gas Chemical Company, Inc.) (Delaney and Onderdonk, 1997; Van Horn et al., 1997 ) with a PouchAnaero anaerobic gas generating system and an RT AnaeroIndicator before transferring to a CO 2 filled Aldrich AtmosBag (glove bag) that was connected to a CO 2 cylinder to create an anaerobic environment. An RT AnaeroIndicator was placed inside the bag to monitor the anaerobic conditions. Dulbecco's phosphate buffered saline (DPBS) was degassed by bubbling nitrogen gas through the solution overnight. The fecal samples were diluted with the DPBS to a concentration of ~100 mg/mL under a CO 2 atmosphere. The samples were mixed by vortexing 
Results

Excretion of Radioactivity
Following a single oral dose of [ 14 C]paritaprevir (200 mg and 100 µCi, with 100 mg ritonavir) to four healthy volunteers, the excretion of radioactivity in urine and feces from all the subjects was measured up to 192 hours post dose. The mean cumulative percent of radioactive dose recovered in urine and feces is illustrated in Fig. 2 . The overall mean recovery of radioactivity in urine and feces samples was 96.5% over the 192-hour study, with recovery in individual subjects ranging from 96.0 to 96.9%. Most of the administered radioactivity was recovered in the first 120 hours post dose (90.5%). The radioactivity was excreted primarily through fecal elimination (mean, 87.8% of dose). Renal excretion was relatively minor (mean, 8.76% of dose).
Pharmacokinetic Data Analysis
The pharmacokinetic parameters for paritaprevir, ritonavir and total radioactivity are summarized in Table 1 . The concentration of total radioactivity was measured by LSC, expressed as ng-equivalent/g. The concentrations of paritaprevir and ritonavir were determined using a validated LC-MS/MS bioanalytical method, expressed as ng/mL. Paritaprevir and total radioactivity T max occurred approximately 3-4 hours following single oral dose. Mean peak plasma concentration (C max ) for the paritaprevir and total radioactivity were 886 ng/mL and 1155
ng-eq/g, respectively. The concentrations of paritaprevir and total radioactivity apparently declined in parallel after reaching the peak concentration (Fig. 3) . The AUC 0-last for the parent drug and total radioactivity were 4610 ± 3440 ng•h/mL and 4960±3600 ng-eq•h/g, respectively.
The AUC 0-last of paritaprevir measured by LC-MS bioanalytical method represents greater than 90% of total plasma radioactivity AUC, suggesting that paritaprevir is the primary component in circulation. Table 2 . Unchanged parent drug represented average 90.1% of radioactivity in the pooled plasma and metabolite M2 accounted for ~6.5% of drug-related material in plasma. Other metabolites include M29 (2.1% of total radioactivity in plasma) and M3 (1.2% of total radioactivity in plasma).
Metabolite Profiles of [
Urine and feces. Chromatographic evaluation of urine samples showed similar metabolites identified in human plasma, including paritaprevir, M2, M13 and M29. After 72 hr post dose to the last collection time point 144-168 hr, M13 was the only radiochemical component detected in urine. The representative HPLC radiochromatogram of pooled human urine is shown in Fig. 5A ).
M13 was the most significant component in urine throughout entire sample collection period,
accounting for 8.6% of dose; unchanged parent drug and other metabolites were present at low to trace levels with respect to the administered dose. The mean quantification results for paritaprevir and metabolites in urine and feces, expressed as the percentages of the administered radioactive dose, are tabulated in Table 3 .
The representative HPLC radiochromatogram of pooled human feces is shown in Fig.5B .
Paritaprevir was extensively degraded in feces. Unchanged parent drug only accounted for 1.1%
of total dose, while M29 was the most abundant radiochemical component in feces, accounting for 59.9% of total dose, followed by M2 (8.6%) and co-eluting metabolites M3/M18 (7.5%).
Other minor radiochemical components in feces included M24, M22, M23, M13, M14, M17, and M6 (each ≤ 3.3% of dose) ( Table 3 ). The proposed metabolic scheme for paritaprevir in humans is shown in Fig. 6 .
LC-MS/MS Characterization of the Metabolites
As described under Method for Metabolite Profiles and Identification, metabolites of paritaprevir were characterized using a combination of positive ionization high resolution full scan MS and product ion scan (MS/MS) analyses. The structures of the metabolite M2 and M13 were confirmed against the reference materials and the structures of other metabolites were proposed based on the high resolution MS/MS fragmentation pattern analysis. The approximate retention time and key mass spectral fragmentation of paritaprevir and metabolites are listed in Table 4 . Metabolite M14, M16, M18, M19, M21. M14, M16, M18, M19 and M21 were only detected in feces at low levels; most of these were below radiochemical detection limit. These metabolites gave protonated molecular ion at m/z 679.2863, which is consistent with the predicted formula of C 37 H 39 N 6 O 7 + (calculated mass 679.2875). CID spectra of M14 and M19
showed the presence of fragment ion at m/z 468.2240 (loss of phenanthridine-diol), indicating hydroxylation occurred at phenanthridine moiety. The hydroxylation position for M16, M18 and M21 was not further characterized due to the fact that overall abundance of these metabolites is low in feces.
Metabolite M15, M17, M20. M15, M17 and M20 were also exclusively detected in feces at trace to low levels. dosing with paritaprevir/ritonavir in humans. Eight subjects received a 300 mg dose of paritaprevir, in combination with a 100 mg dose of ritonavir once daily for 14 consecutive days.
Paritaprevir peak plasma concentrations averaged 6398 ng/ml (Table 5) 
In vitro hydrolysis in simulated intestinal fluids
The stability of paritaprevir in simulated intestinal fluids was evaluated by incubating radiochromatographic analysis indicated that paritaprevir was stable in both FaSSIF and FeSSIF solutions; no hydrolysis products were detected, indicating sulfonamide or amide hydrolysis is unlikely to occur chemically in human intestinal fluids either under fast or fed conditions.
Metabolite formation in in vitro human hepatocyte incubation
The in vitro metabolite profile in human hepatocytes was evaluated by incubations of [ 14 C]paritaprevir with or without cytochrome P450 inhibitors (ritonavir or 1-aminobenzotriazole).
As shown in Fig. 8 (a & b) , [ 
Discussion
The mass balance, disposition and metabolism of paritaprevir were evaluated in four healthy human subjects. Following administration of a single 200-mg oral dose of [ 14 C] paritaprevir, coadministered with a single 100-mg oral dose of ritonavir, the mean total recovery of administered radioactive dose was 96.5%, with recovery in individual subjects ranging from 96.0 to 96.9%.
The majority of the administered radioactive dose (87.8%) was excreted in feces. Renal elimination plays a minor role, since radioactivity recovered in urine only accounted for 8.8% of
dose, indicating that paritaprevir and metabolites are primarily eliminated in humans through hepatobiliary and fecal elimination routes.
Metabolites of paritaprevir in plasma, urine and feces were profiled using HPLC-radioactivity detection and structures of metabolites were characterized using HPLC-high resolution mass spectrometry. Biotransformation of paritaprevir in humans involves: 1) CYP-mediated oxidation on the olefinic linker, the phenanthridine group, the methylpyrazinyl group, or combinations thereof; 2) amide hydrolysis at the acyl cyclopropane-sulfonamide moiety and the pyrazine-2-carboxyamide moiety. The CYP-mediated oxidation of paritaprevir is greatly attenuated with ritonavir co-dosing via inhibition of CYP3A-mediated first pass metabolism.
Of the total radioactivity excreted in feces, the acyl sulfonamide hydrolysis product M29 was the primary radiochemical component (~60% of dose), followed by the oxidative metabolite M2 
